Found: 974
Select item for more details and to access through your institution.
Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink‐6 randomized clinical trial.
- Published in:
- Cardiovascular Diabetology, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12933-024-02344-6
- By:
- Publication type:
- Article
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.
- Published in:
- Nephrology Dialysis Transplantation, 2024, v. 39, n. 9, p. 1504, doi. 10.1093/ndt/gfae032
- By:
- Publication type:
- Article
New pharmacological approaches to diabetes management.
- Published in:
- Practice Nursing, 2015, v. 26, n. 3, p. 140, doi. 10.12968/pnur.2015.26.3.140
- By:
- Publication type:
- Article
Assessing early tubular protective effects of SGLT2 inhibitor empagliflozin against type 2 diabetes mellitus using functional magnetic resonance imaging.
- Published in:
- Acta Diabetologica, 2024, v. 61, n. 4, p. 473, doi. 10.1007/s00592-023-02220-x
- By:
- Publication type:
- Article
Effect of sodium–glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis.
- Published in:
- Acta Diabetologica, 2023, v. 60, n. 2, p. 191, doi. 10.1007/s00592-022-01981-1
- By:
- Publication type:
- Article
Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.
- Published in:
- Acta Diabetologica, 2022, v. 59, n. 4, p. 575, doi. 10.1007/s00592-021-01823-6
- By:
- Publication type:
- Article
Empagliflozin, metformin and insulin degludec, during pregnancy: a case report.
- Published in:
- Acta Diabetologica, 2018, v. 55, n. 7, p. 759, doi. 10.1007/s00592-018-1134-y
- By:
- Publication type:
- Article
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
- Published in:
- Acta Diabetologica, 2017, v. 54, n. 1, p. 19, doi. 10.1007/s00592-016-0892-7
- By:
- Publication type:
- Article
A NOVEL VALIDATED STABILITY INDICATING METHOD FOR QUANTIFICATION OF EMPAGLIFLOZIN IN BULK AND MARKETED FORMULATION BY HPTLC APPLYING EXPERIMENTAL DESIGN APPROACH.
- Published in:
- Indian Drugs, 2023, v. 60, n. 6, p. 66, doi. 10.53879/id.60.06.13038
- By:
- Publication type:
- Article
Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes.
- Published in:
- Healthcare (2227-9032), 2022, v. 10, n. 7, p. 1153, doi. 10.3390/healthcare10071153
- By:
- Publication type:
- Article
Empagliflozin alone and in combination with metformin ameliorate diabetes type 2-oxidative stress.
- Published in:
- Kufa Journal for Veterinary Medical Sciences, 2023, v. 14, n. 2, p. 33, doi. 10.36326/kjvs/2023/v14i213388
- By:
- Publication type:
- Article
Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways.
- Published in:
- Journal of Immunology Research, 2021, p. 1, doi. 10.1155/2021/9944880
- By:
- Publication type:
- Article
Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF- B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
Empagliflozin Effects in Patients with ST-Elevation Myocardial Infarction Undergoing Primary PCI: The EMI-STEMI Randomized Clinical Trial.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 5, p. 673, doi. 10.1007/s40256-024-00662-4
- By:
- Publication type:
- Article
Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 3, p. 455, doi. 10.1007/s40256-024-00648-2
- By:
- Publication type:
- Article
Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 6, p. 609, doi. 10.1007/s40256-023-00601-9
- By:
- Publication type:
- Article
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 3, p. 323, doi. 10.1007/s40256-023-00578-5
- By:
- Publication type:
- Article
Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 1, p. 47, doi. 10.1007/s40256-022-00550-9
- By:
- Publication type:
- Article
Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 5, p. 577, doi. 10.1007/s40256-022-00542-9
- By:
- Publication type:
- Article
Cardiac Late Sodium Channel Current (Late-I<sub>Na</sub>) is a Molecular Target in the Heart for the Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitor Empagliflozin, Contributing to Cardioprotection.
- Published in:
- Rhythmos, 2021, v. 16, n. 3, p. 68
- By:
- Publication type:
- Article
EMPA-TROPISM: Empagliflozin in Nondiabetic HFrEF Patients Significantly Improves LV Volumes, LV Mass, LV Systolic Function, Functional Capacity, and Quality of Life When Compared With Placebo.
- Published in:
- Rhythmos, 2021, v. 16, n. 2, p. 43
- By:
- Publication type:
- Article
EMPA-REG Outcome Trial: Hypoglycemia Increases Risk of HF Hospitalization (HFH) and MI/Hypoglycemia Risk was not Increased with Empagliflozin and Incident Hypoglycemia did not Attenuate its Cardio-Protective Effects.
- Published in:
- Rhythmos, 2020, v. 15, n. 2, p. 39
- By:
- Publication type:
- Article
EMPA-REG OUTCOME Trial: Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 41
- By:
- Publication type:
- Article
ODYSSEY Outcomes: The Price of Alirocumab Would Have to be Reduced Drastically to be Cost-Effective.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 40
- By:
- Publication type:
- Article
Empagliflozin and Dapagliflozin Increase Na + and Inward Rectifier K + Current Densities in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells (hiPSC-CMs).
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 23, p. 3707, doi. 10.3390/cells11233707
- By:
- Publication type:
- Article
Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 21, p. 3372, doi. 10.3390/cells11213372
- By:
- Publication type:
- Article
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 19, p. 3107, doi. 10.3390/cells11193107
- By:
- Publication type:
- Article
Empagliflozin Protects HK-2 Cells from High Glucose-Mediated Injuries via a Mitochondrial Mechanism.
- Published in:
- Cells (2073-4409), 2019, v. 8, n. 9, p. 1085, doi. 10.3390/cells8091085
- By:
- Publication type:
- Article
Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 8, p. 1, doi. 10.1111/dme.15383
- By:
- Publication type:
- Article
Epigastric pain and partial ptosis.
- Published in:
- 2023
- By:
- Publication type:
- Test/Instrument
Clinical care and other categories posters: Ethnicity.
- Published in:
- Diabetic Medicine, 2021, v. 38, p. 1, doi. 10.1111/dme.35_14556
- Publication type:
- Article
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 4, p. 593, doi. 10.1111/dme.14262
- By:
- Publication type:
- Article
Use of glucose‐lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose‐lowering drug groups.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 12, p. 1612, doi. 10.1111/dme.14117
- By:
- Publication type:
- Article
Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 11, p. 1494, doi. 10.1111/dme.14076
- By:
- Publication type:
- Article
Diabetes management gains: teaching old dogs new tricks.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 9, p. 1072, doi. 10.1111/dme.14068
- By:
- Publication type:
- Article
SGLT2 inhibitors in Type 1 diabetes: is this the future?
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 12, p. 1642, doi. 10.1111/dme.13791
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic profile of thesodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 8, p. 1096, doi. 10.1111/dme.13629
- By:
- Publication type:
- Article
Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes.
- Published in:
- Diabetic Medicine, 2017, v. 34, n. 11, p. 1646, doi. 10.1111/dme.13508
- By:
- Publication type:
- Article
Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1393946
- By:
- Publication type:
- Article
A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1363501
- By:
- Publication type:
- Article
Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3466, doi. 10.1111/dom.15634
- By:
- Publication type:
- Article
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2578, doi. 10.1111/dom.15572
- By:
- Publication type:
- Article
Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on empagliflozin (Empa‐AA): Insights from real‐world data.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 5, p. 1830, doi. 10.1111/dom.15499
- By:
- Publication type:
- Article
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 4, p. 1291, doi. 10.1111/dom.15429
- By:
- Publication type:
- Article
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 1033, doi. 10.1111/dom.15404
- By:
- Publication type:
- Article
Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 532, doi. 10.1111/dom.15339
- By:
- Publication type:
- Article
The effect of empagliflozin and fenofibrate therapies, alone and in combination, on the serum urate concentration in hyperuricaemic type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 1, p. 385, doi. 10.1111/dom.15295
- By:
- Publication type:
- Article
Albuminuria‐lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo‐controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 1, p. 54, doi. 10.1111/dom.15287
- By:
- Publication type:
- Article
Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3538, doi. 10.1111/dom.15249
- By:
- Publication type:
- Article